Researchers now know that MS starts way earlier than the clinical onset, creating the real possibility that MS could one day be controlled.

At ASHG in Boston, Eric Green received the society's Leadership Award and delivered an acceptance speech that moved the entire room.

Study findings suggest using the drug PF-06409577 to restore CDX2 in colon cancers could cut risk of recurrence and death by up to 50%.

BioAgilytix now operates 355,000-square-feet of laboratory facilities, including 24,000-square-feet dedicated to LC/MS.

Genomics unveils Mystra at ASHG 2025—an AI genetics platform to accelerate drug discovery and clinical validation using large-scale genetic data.

In this GEN interview, Nobel Laureate David Baker, PhD, emphasizes that designing proteins from scratch is reality and unpacks what's needed for AI to transform medicine.